Abstract Number: 906 • 2016 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Background/Purpose: Several Clinical trials indicate that Methotrexate (MTX) could be considered as a feasible option in addition to corticosteroids for patients with GCA, but there…Abstract Number: 968 • 2016 ACR/ARHP Annual Meeting
Urinary Soluble CD163, an M2 Macrophage Marker, Reflects the Renal Disease Activity in Lupus Nephritis: A Cross Sectional and Longitudinal Assessment
Background/Purpose: Alternatively activated (M2) macrophages are the major macrophage subtype infiltrating the glomeruli in lupus nephritis (LN). CD163 is a marker of M2 macrophages. In…Abstract Number: 1019 • 2016 ACR/ARHP Annual Meeting
The Impact of Hip and Knee Osteoarthritis on the Subsequent Risk of Incident Diabetes: A Population-Based Cohort Study
Background/Purpose: Osteoarthritis (OA) and diabetes commonly co-occur. Potential explanations include common risk factors (aging, obesity) and the effects of OA-related functional limitations on diabetes risk…Abstract Number: 1221 • 2016 ACR/ARHP Annual Meeting
Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative
Background/Purpose: Patient registries both disease-and drug-based complement information obtained from clinical trials. Long-term outcomes studies can provide information useful for patients. The Agency for Healthcare…Abstract Number: 1984 • 2016 ACR/ARHP Annual Meeting
Which Factors Associate with Localized Knee Pain and Generalized Pain: A 10-Year Longitudinal Study?
Background/Purpose: The correlates of localized knee pain (KP) and multi-site pain (MSP) have been clearly demonstrated; however, whether these factors also contribute to intermittent or…Abstract Number: 2019 • 2016 ACR/ARHP Annual Meeting
Faces in Motion: Clinical Subtyping in Scleroderma Using Changes in Forced Vital Capacity
Background/Purpose: Prognostication in scleroderma has historically depended on using static measures such as antibody status and extent of skin involvement to stratify risk of mortality…Abstract Number: 2168 • 2016 ACR/ARHP Annual Meeting
Metabolic Syndrome, All Cause Mortality and Atherosclerotic Cardiovascular Disease in Rheumatic Diseases
Background/Purpose: all-cause and cardiovascular mortality and cardiovascular morbidity are reportedly increased in rheumatic diseases, both inflammatory and non-inflammatory. Few studies, however have addressed the impact…Abstract Number: 2184 • 2016 ACR/ARHP Annual Meeting
Evidence Based Physical Activity Threshold to Predict Improved/High Function in Older Adults with Lower Extremity Conditions: The Osteoarthritis Initiative
Background/Purpose: Physical activity guidelines for adults stipulate at least 150 minutes/week moderate-to-vigorous (MV) intensity physical activity acquired in bouts lasting 10 minutes or more…Abstract Number: 2196 • 2016 ACR/ARHP Annual Meeting
Trajectories and Predictors of Fear-Avoidance in Persons with Rheumatoid Arthritis. a Longitudinal Observational Study
Trajectories and Predictors of Fear-Avoidance in Persons With Rheumatoid Arthritis. A Longitudinal Observational Study Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with…Abstract Number: 2370 • 2016 ACR/ARHP Annual Meeting
Factors Affecting Interval Changes in Perceived Fatigue over Five Years in Patients with Rheumatoid Arthritis Compared with Osteoarthritis
Background/Purpose: In a previous cross-sectional study we noted higher fatigue levels in patients with advanced lower limb OA compared with RA, and identified differences in…Abstract Number: 3132 • 2016 ACR/ARHP Annual Meeting
Protective Effects of Replacing Sedentary Time with Light and Moderate to Vigorous Physical Activity on Functional Limitation in Knee OA
Background/Purpose: Physical activity protects the development of functional limitation in knee osteoarthritis (OA). But little is known about the protective effects of physical activity intensity,…Abstract Number: 3212 • 2016 ACR/ARHP Annual Meeting
Treat-to-Target in RA: Does Early Simplified Disease Activity Index (SDAI) Remission Lead to Better 5-Year Functional Outcomes Than SDAI Low Disease Activity?
Background/Purpose: The management of rheumatoid arthritis (RA) has evolved considerably during the last couple of decades, with current recommended practice being a treat-to-target approach, involving…Abstract Number: 31 • 2015 ACR/ARHP Annual Meeting
Risk of Chronic Obstructive Pulmonary Disease in Rheumatoid Arthritis: A Population Based Cohort Study
Background/Purpose: A link between chronic obstructive pulmonary disease (COPD) and inflammation has been established in a number of studies. This raises the question of whether…Abstract Number: 392 • 2015 ACR/ARHP Annual Meeting
From Childhood to Adulthood: Longitudinal Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Background/Purpose: Outcomes of patients with cSLE over time and into adulthood are poorly understood. There has been no information about the longitudinal trajectory of organ…Abstract Number: 395 • 2015 ACR/ARHP Annual Meeting
Depression Risk Among Adults with Childhood- and Adult-Onset Systemic Lupus Erythematosus: 11 Years of Follow-up
Background/Purpose: Neuropsychiatric syndromes are prevalent in childhood-onset systemic lupus erythematosus (cSLE), but the long-term risk of depression in adults with cSLE is unknown. We compared…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 17
- Next Page »